BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 28545466)

  • 21. Perioperative epidural analgesia is not associated with increased survival from renal cell cancer, but overall survival may be improved: a retrospective chart review.
    Kovac E; Firoozbakhsh F; Zargar H; Fergany A; Elsharkawy H
    Can J Anaesth; 2017 Jul; 64(7):754-762. PubMed ID: 28417354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
    You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel Predictor of Survival with Renal Cell Carcinoma After Nephrectomy.
    Peng D; He ZS; Li XS; Tang Q; Zhang L; Yang KW; Yu XT; Zhang CJ; Zhou LQ
    J Endourol; 2017 Apr; 31(4):397-404. PubMed ID: 28121179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
    Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
    Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
    Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
    World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
    Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
    Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma.
    Mano R; Flynn J; Blum KA; Silagy AW; DiNatale RG; Marcon J; Wang A; Sanchez A; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
    Urol Oncol; 2019 Dec; 37(12):916-923. PubMed ID: 31590969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Sharma P; Zargar-Shoshtari K; Caracciolo JT; Fishman M; Poch MA; Pow-Sang J; Sexton WJ; Spiess PE
    Urol Oncol; 2015 Aug; 33(8):339.e17-23. PubMed ID: 26094169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cytoreductive Partial Nephrectomy versus Cytoreductive Radical Nephrectomy for Locally T
    Xiong SC; Shao YX; Hu X; Yang WX; Dou WC; Li X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 Jul; 51(4):546-551. PubMed ID: 32691565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting.
    Ljungberg B; Sundqvist P; Lindblad P; Kjellman A; Thorstenson A; Hellström M; Kröger Dahlin BI; Thomasson M; Harmenberg U; Lundstam S
    Scand J Urol; 2020 Dec; 54(6):487-492. PubMed ID: 32897123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytoreductive Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma in the Targeted Therapy Era.
    Uprety D; Bista A; Smith AL; Vallatharasu Y; Marinier DE
    Anticancer Res; 2018 May; 38(5):3013-3018. PubMed ID: 29715133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of nutritional deficiency on prognosis of renal cell carcinoma (RCC).
    Ko K; Park YH; Lee JW; Ku JH; Kwak C; Kim HH
    BJU Int; 2013 Oct; 112(6):775-80. PubMed ID: 24028765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Laukhtina E; Pradere B; D'Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Schuettfort VM; Enikeev D; Shariat SF
    Minerva Urol Nephrol; 2022 Jun; 74(3):329-336. PubMed ID: 33769012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
    Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
    Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.
    Xiao WJ; Zhu Y; Dai B; Zhang HL; Ye DW
    Int Braz J Urol; 2015; 41(2):288-95. PubMed ID: 26005970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
    Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
    Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low preoperative serum cholesterol level is associated with aggressive pathologic features and poor cancer-specific survival in patients with surgically treated renal cell carcinoma.
    Kang HW; Seo SP; Kim WT; Yun SJ; Lee SC; Kim WJ; Hwang EC; Kang SH; Hong SH; Chung J; Kwon TG; Kim HH; Kwak C; Byun SS; Kim YJ;
    Int J Clin Oncol; 2018 Feb; 23(1):142-150. PubMed ID: 28791497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
    Bamias A; Tzannis K; Papatsoris A; Oudard S; Beuselinck B; Escudier B; Liontos M; Elaidi TR; Chrisofos M; Stravodimos K; Anastasiou I; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamia C
    Clin Genitourin Cancer; 2014 Oct; 12(5):373-83. PubMed ID: 24819319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.